A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group.

PubWeight™: 4.33‹?› | Rank: Top 1%

🔗 View Article (PMID 1569973)

Published in N Engl J Med on May 21, 1992

Authors

E J Lewis1, L G Hunsicker, S P Lan, R D Rohde, J M Lachin

Author Affiliations

1: Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL.

Articles citing this

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57

Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol (2007) 1.39

Small vessel vasculitis of the lung. Thorax (2000) 1.25

Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr Nephrol (2003) 1.16

Desperate diseases and plasmapheresis. N Engl J Med (1992) 1.06

Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity (2010) 0.98

Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis (2014) 0.92

Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin Rheumatol (2004) 0.90

IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis (2005) 0.89

Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option. Clin J Am Soc Nephrol (2009) 0.88

Retrospective study of plasma exchange in patients with idiopathic rapidly progressive glomerulonephritis and vasculitis. Arch Dis Child (1996) 0.88

Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis (2003) 0.87

Lupus nephritis: an update. Clin Exp Nephrol (2015) 0.86

Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus (2012) 0.85

Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant (2010) 0.83

Lupus vasculopathy combined with acute renal failure in lupus nephritis. Pediatr Nephrol (2003) 0.82

Slowing chronic kidney disease progression: results of prospective clinical trials in adults. Pediatr Nephrol (2008) 0.81

Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol (2013) 0.81

Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus. Rheumatol Int (2005) 0.80

Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis. Rheumatol Int (2014) 0.79

The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol (2015) 0.79

The treatment of systemic lupus proliferative nephritis. Pediatr Nephrol (2012) 0.79

Lupus nephropathy and cardiopulmonary and hepatic dysfunctions in a child. Pediatr Nephrol (2006) 0.78

Advances in apheresis therapy for glomerular diseases. Clin Exp Nephrol (2007) 0.78

Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs (2010) 0.78

A treatment algorithm for children with lupus nephritis to prevent developing renal failure. Int J Prev Med (2014) 0.77

Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol (2013) 0.77

Role of therapeutic apheresis and phlebotomy techniques in anaesthesia and critical care. Indian J Anaesth (2014) 0.77

Retrospective study of plasma exchange in children with systemic lupus erythematosus. Pediatr Nephrol (2004) 0.77

[Lupusnephritis]. Z Rheumatol (2012) 0.77

Dramatic response to plasma exchange in systemic lupus erythematosus with acute complications: Report of two cases. Indian J Crit Care Med (2013) 0.76

Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis. Oncotarget (2016) 0.76

Notes on the kidney and its diseases for the neurologist. J Neurol Neurosurg Psychiatry (2007) 0.75

Evidence-based Medicine:: An overview. J Sci Res Med Sci (2001) 0.75

Immune-mediated necrotizing myopathy, associated with antibodies to signal recognition particle, together with lupus nephritis: case presentation and management. J Clin Med Res (2015) 0.75

Deterioration of renal function in a patient with lupus. Ann Rheum Dis (1994) 0.75

Plasmapheresis for lupus nephritis. Lupus Plasmapheresis Study Group. N Engl J Med (1992) 0.75

Plasmapheresis for lupus nephritis. N Engl J Med (1992) 0.75

Plasma exchange for concurrent lupus nephritis and antiphospholipid syndrome. Clin Kidney J (2014) 0.75

Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis. Arthritis Res Ther (2016) 0.75

The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long-Term Outcome in Patients with Severe Lupus Nephritis. Nephron Extra (2016) 0.75

Pharmacodynamic monitoring of (immuno)proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis. Lupus Sci Med (2015) 0.75

Recent advances in the treatment of lupus nephritis. Clin Exp Nephrol (2011) 0.75

Plasmapheresis for lupus nephritis. N Engl J Med (1992) 0.75

Plasmapheresis for lupus nephritis. N Engl J Med (1992) 0.75

Articles by these authors

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Implementation of group sequential logrank tests in a maximum duration trial. Biometrics (1990) 6.32

Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials (1981) 6.06

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med (1995) 5.50

Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3). J Immunol (1973) 4.78

The effect of the volume of procedures at transplantation centers on mortality after liver transplantation. N Engl J Med (1999) 4.03

Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics (1986) 3.03

Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis (1990) 2.91

Properties of the urn randomization in clinical trials. Control Clin Trials (1988) 2.81

Properties of permuted-block randomization in clinical trials. Control Clin Trials (1988) 2.76

The impact of comorbid and sociodemographic factors on access to renal transplantation. JAMA (1993) 2.54

Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33

Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int (2006) 2.18

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int (2001) 2.17

Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. A controlled trial of efficacy and safety. Ann Intern Med (1981) 2.17

Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol (1999) 1.95

OPTN policy regarding prioritization of patients with hepatopulmonary syndrome: does it provide equitable organ allocation? Am J Transplant (2008) 1.88

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int (1999) 1.82

C3b inactivator of man. 3. Further purification and production of antibody to C3b INA. J Immunol (1972) 1.64

The role of monocytes in serum sickness nephritis. J Exp Med (1979) 1.55

Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (2000) 1.50

Use of the serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy. Collaborative Study Group of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy. Am J Kidney Dis (1990) 1.49

Design and statistical issues of the Modification of Diet in Renal Disease Trial. The Modification of Diet in Renal Disease Study Group. Control Clin Trials (1991) 1.45

Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group. Am J Kidney Dis (1999) 1.37

Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis (1996) 1.31

The natural history of cholelithiasis: the National Cooperative Gallstone Study. Ann Intern Med (1984) 1.28

The effect of transplant center volume on cardiac transplant outcome. A report of the United Network for Organ Sharing Scientific Registry. JAMA (1994) 1.28

Short- and long-term outcomes with the use of kidneys and livers donated after cardiac death. Am J Transplant (2006) 1.27

Center-specific graft and patient survival rates: 1997 United Network for Organ Sharing (UNOS) report. JAMA (1998) 1.27

The impact of HLA mismatches on the survival of first cadaveric kidney transplants. N Engl J Med (1994) 1.26

The use of response-adaptive designs in clinical trials. Control Clin Trials (1993) 1.25

Pretreatment biliary lipid composition in white patients with radiolucent gallstones in the National Cooperative Gallstone Study. Gastroenterology (1982) 1.14

Increased frequency of posttransplant lymphomas in patients treated with cyclosporine, azathioprine, and prednisone. Transplantation (1989) 1.12

The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis (1995) 1.12

Sample size determinants for r X c comparative trials. Biometrics (1977) 1.07

Acute reversible proteinuria induced by infusion of the polycation hexadimethrine. Kidney Int (1981) 1.04

Delayed graft function: state of the art, November 10-11, 2000. Summit meeting, Scottsdale, Arizona, USA. Am J Transplant (2001) 1.02

National Cooperative Gallstone Study: the effect of chenodeoxycholic acid on lipoproteins and apolipoproteins. Gastroenterology (1982) 1.02

Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis (1999) 1.02

Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med (1992) 1.01

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant (2000) 0.98

A prospective morphologic evaluation of hepatic toxicity of chenodeoxycholic acid in patients with cholelithiasis: the National Cooperative Gallstone Study. Hepatology (1982) 0.95

Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int (1992) 0.95

Temporal changes of MR findings in central pontine myelinolysis. AJNR Am J Neuroradiol (1995) 0.93

Glomerular sieving of anionic and neutral bovine albumins in proteinuric rats. Kidney Int (1985) 0.93

Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis. Am J Kidney Dis (1989) 0.92

Assessment of stratum-covariate interactions in Cox's proportional hazards regression model. Stat Med (1986) 0.91

Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int (1994) 0.90

Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis (1993) 0.89

Low-dose chenodiol to prevent gallstone recurrence after dissolution therapy. Ann Intern Med (1984) 0.88

The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy. A meta-analysis of individual patient data. Diabetes Care (1996) 0.88

The effects of chenodiol on biliary lipids and their association with gallstone dissolution in the National Cooperative Gallstone Study (NCGS). J Clin Invest (1984) 0.87

Sulfation of lithocholate as a possible modifier of chenodeoxycholic acid-induced elevations of serum transaminase in patients with gallstones. J Clin Invest (1981) 0.86

Ultrastructural evidence of intrahepatic cholestasis before and after chenodeoxycholic acid therapy in patients with cholelithiasis: the national cooperative gallstone study. Hepatology (1983) 0.85

Acute respiratory illness in families exposed to nitrogen dioxide ambient air pollution in Chattanooga, Tennessee. Arch Environ Health (1982) 0.85

Polycation binding to glomerular basement membrane. Effect of biochemical modification. Lab Invest (1987) 0.85

Muromonab-CD3 (Orthoclone OKT3): the first monoclonal antibody approved for therapeutic use. Iowa Med (1987) 0.84

Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med (1991) 0.84

A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group. J Am Soc Nephrol (1992) 0.83

Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation (1996) 0.83

Report of a case of Goodpasture's syndrome with unusual immunohistology and antibody reactivity. Clin Immunol Immunopathol (1981) 0.83

A survival advantage for renal transplantation. N Engl J Med (1999) 0.83

Effect of blood transfusions on cadaver renal allograft survival. Transplant Proc (1979) 0.82

Simultaneous pancreas-kidney versus kidney-alone transplants in diabetics: increased risk of early cardiac death and acute rejection following pancreas transplants. Clin Transplant (1994) 0.82

Glomerular sieving of high molecular weight proteins in proteinuric rats. Kidney Int (1987) 0.82

Design and methodological considerations in the National Cooperative Gallstone Study: a multicenter clinical trial. Control Clin Trials (1981) 0.81

Appearance of type II diabetes mellitus in type I diabetic recipients of pancreas allografts. Transplantation (1989) 0.80

The pharmacology of the antimalarials. A rational approach to the therapy of resistant falciparum malaria. Arch Intern Med (1969) 0.80

Sequential monitoring of survival data with the Wilcoxon statistic. Biometrics (1995) 0.80

A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis (2001) 0.80

Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Prog Clin Biol Res (1990) 0.80

Heart rate and blood pressure in black newborns and in white newborns. Pediatrics (1976) 0.80

Group sequential distribution-free methods for the analysis of multivariate observations. Biometrics (1992) 0.79

Comparison of the serum and intracellular pharmacokinetics of azithromycin in healthy and diabetic volunteers. Pharmacotherapy (2000) 0.79

Sudden hearing loss associated with tacrolimus in a kidney-pancreas allograft recipient. Pharmacotherapy (1999) 0.78

The lack of relationship between hepatotoxicity and lithocholic-acid sulfation in biliary bile acids during chenodiol therapy in the National Cooperative Gallstone Study. Hepatology (1991) 0.78

A study of acute respiratory disease in families exposed to different levels of Air pollution in the Great Salt Lake basin, Utah, 1971-1972 and 1972-1973. Environ Health Perspect (1982) 0.78

On stepwise discriminant analyses applied to physiologic data. Psychophysiology (1974) 0.77

Newborn offspring of a schizophrenic parent: cardiac reactivity to auditory stimuli. Psychophysiology (1975) 0.77

Stainable glomerular basement membrane polyanions and renal hemodynamics during hexadimethrine-induced proteinuria. J Lab Clin Med (1984) 0.77

External monitoring of a data coordinating center: experience of the National Cooperative Gallstone Study. Control Clin Trials (1987) 0.77

Protein calculation from food diaries of adult humans underestimates values determined using a biological marker. J Nutr (1995) 0.77

Use of spending functions for occasional or continuous monitoring of data in clinical trials. Stat Med (1993) 0.77

Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study. Control Clin Trials (1992) 0.77

Urinary albumin excretion after donor nephrectomy. Am J Kidney Dis (1985) 0.77

Increased frequency of posttransplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplant Proc (1989) 0.76

Acute renal failure following halothane anesthesia. Arch Pathol Lab Med (1976) 0.76

Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Pharmacotherapy (1998) 0.75

Effect of air pollution on chronic respiratory disease in the New York city metropolitan area, 1972. Environ Health Perspect (1981) 0.75

Chronic rejection in renal allografts: importance of cardiovascular risk factors. Clin Transplant (1995) 0.75

The role of complement in glomerulonephritis. Mil Med (1975) 0.75